Quidel Corporation (Nasdaq: QDEL) is a California-based manufacturer of diagnostic healthcare solutions serving to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.
Quidel is 35 years young, with commercialized products in the healthcare market since 1984. Originally known for lateral flow products used in physicianâ€™s offices, our product lines have expanded through robust product development to include tests in infectious disease and reproductive health that are used in hospitals, reference labs, and clinics as well. Our current products fall generally into these categories: (1) lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (4) molecular diagnostic products.
Whether at our headquarters in San Diego, California, at our research and manufacturing operations in Ohio, Massachusetts, and Germany, or through our Commercial organization around the world, the Company is delivering a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody testing to molecular diagnostic tests that further improve the quality of healthcare.
Closing share price
|FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|$175.4 m||$182.6 m||$196.1 m||$191.6 m|
Revenue growth, %
|$7.4 m||($7.1 m)||($6.1 m)||($13.8 m)|